Indications

Antibiotic

Contraindication

Hypersensitivity to ciprofloxacin or other quinolones. Concomitant admin w/ tizanidine.

Special Precautions

Patient w/ epilepsy, history of CNS disorders, G6PD deficiency, known prolongation of QT interval, w/ risk factors for QT interval prolongation or torsades de pointes (e.g. congenital long QT syndrome, uncorrected electrolyte imbalance, cardiac disease). May exacerbate myasthenia gravis symptoms. Kidney, heart or lung transplant recipients. Hepatic and renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, if affected do not drive or operate machinery. Maintain adequate fluid intake and avoid excessive alkalinity of urine. Avoid exposure to sunlight or artificial UV light (e.g. tanning beds). Rest and refrain from exercise at 1st sign of tendinitis or tendon rupture (e.g. pain, swelling). Monitoring Parameters Periodic monitoring of renal, hepatic and hematopoietic function during prolonged therapy.

Side Effects

Nausea, vomiting, diarrhoea, abdominal pain, dyspepsia; headache, dizziness, confusion, insomnia, restlessness; tremor, drowsiness, nightmares, hallucinations, psychotic reactions, depression, convulsions, intracranial HTN; paraesthesia, peripheral neuropathy; rash, pruritus, photosensitivity; anaphylaxis; crystalluria, transient increases in serum creatinine or BUN; elevated liver enzyme values, jaundice, and hepatitis; eosinophilia, leucopenia, thrombocytopenia; tachycardia, hypotension, oedema, syncope, hot flushes, and sweating; tendon damage; pain and irritation at the inj site; ocular burning or discomfort, keratopathy, corneal staining, corneal precipitates or infiltrates, photophobia; ear discomfort, pain, or pruritus.

Drug Interactions

May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.

Route of Administration

Oral

Dosage

As directed by the physician